作者
Aksana K Jones, Eliford Ngaimisi, Mathangi Gopalakrishnan, Malcolm A Young, Celine M Laffont
发表日期
2021/4
期刊
Clinical Pharmacokinetics
卷号
60
页码范围
527-540
出版商
Springer International Publishing
简介
Background
BUP-XR (a.k.a. RBP-6000 or SUBLOCADE™) is an extended-release subcutaneous buprenorphine formulation for the treatment of opioid use disorder. BUP-XR was designed to provide sustained buprenorphine exposure throughout the monthly dosing interval, at concentrations sufficient to control all aspects of the disease (withdrawal, craving, and blockade of opioid subjective effects).
Objectives
To characterize the population pharmacokinetics of BUP-XR based on phase II and phase III data and to evaluate whether target therapeutic concentrations were reached with the dosing regimens evaluated in the phase III program.
Methods
The population pharmacokinetic analysis included 570 subjects with opioid use disorder who received up to 12 monthly BUP-XR injections following induction with …
学术搜索中的文章
AK Jones, E Ngaimisi, M Gopalakrishnan, MA Young… - Clinical Pharmacokinetics, 2021